Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12012554 | 1.00 | HSD11B1 (0.43) | HSD11B1F2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2185048 | 1.00 | HSD11B1 (0.43) | HSD11B1F2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2171985 | 0.89 | HSD11B1 (0.37) | HSD11B1F2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2170275 | 0.87 | ALDH1A1 (0.40) | HSD11B1F2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12473581 | 0.81 | POLB (0.39) | HSD11B1F2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13368830 | 0.76 | USP2 (0.39) | EPHX2 | |
| SCHEMBL2169195 | 0.76 | PKM (0.40) | HSD11B1CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL12012553 | 0.76 | KMT2A (0.50) | HSD11B1CYP3A4CYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL2170194 | 0.75 | USP2 (0.38) | CYP1A2CYP3A4CYP2C19EPHX2 | |
| SCHEMBL2169179 | 0.75 | KMT2A (0.39) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2348019-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885F2 2159/4885CYP1A2 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.